SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2011 / Cilt: 41 - Sayı: 2

Hepatitis B, hepatitis C, HIV, and VDRL seroprevalence of blood donors in Mersin

Mersin, Türkiye’de kan donörlerinde hepatitis B, hepatitis C, HIV ve VDRL seroprevalansı

Ahmet Öner KURT
Caferi Tayyar ŞAŞMAZ
Seva ÖNER
Gülçin YAPICI
Resul BUĞDAYCI
Pages
335–341
Publication Date
2022-11-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Seroprevalence increased with age in males.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The aim of this study was to determine the seroprevalence and affecting factors of Hepatitis B surface antigen (HbsAg), hepatitis C virus antibody (anti-HCV), anti human immunodeficiency virus (anti-HIV), and VDRL in blood donors in Mersin.
📊
Key Findings & Data:The medical records of 30,716 blood donors were evaluated.
💡
Conclusion & Impact:Seroprevalence increased with age in males.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:HbsAg · anti-HCV · anti-HIV

Abstract

The aim of this study was to determine the seroprevalence and affecting factors of Hepatitis B surface antigen (HbsAg), hepatitis C virus antibody (anti-HCV), anti human immunodeficiency virus (anti-HIV), and VDRL in blood donors in Mersin. Materials and methods: This was a retrospective, descriptive study. All blood centers in Mersin were included in the study. The medical records of 30,716 blood donors were evaluated. The data were analyzed using descriptive analysis, linear-by-linear association test, and the Pearson chi-square significance test. Results: Of the donors, 691 (2.2%) had positive HbsAg, 125 (0.4%) had positive anti-HCV, and 46 (0.1%) had positive VDRL test. The confirmation test was positive in 1 participant out of 54 (0.2%), whose anti-HIV test was positive. Of the participants, 862 (2.8%) showed at least 1 positive test result. In one participant, both HbsAg and anti-HCV tests were positive. Conclusion: There was at least 1 blood-borne disease seropositivity in 2.8% of the donors. Seroprevalence increased with age in males.

Özet

Amaç: Bu çalışmanın amacı, Mersin’de kan donörlerinde Hepatitis B surface antigen (HbsAg), Hepatitis C virus antibody (anti-HCV), anti Human Immunodefi ciency Virus (anti-HIV) ve VDRL seroprevelanslarını ve etkileyen faktörleribelirlemektir.Yöntem ve gereç: Bu çalışma retrospektif tanımlayıcı bir çalışmadır. Çalışmaya Mersin’deki tüm kan merkezleri alındıve 30716 donörün kayıtları değerlendirildi. Verilerin analizinde tanımlayıcı istatistikler, Linear by linear association testve Pearson Ki-kare önemlilik testleri kullanıldı.Bulgular: Donörlerin 691’inde (% 2,2) HbsAg pozitif, 125’inde (% 0,4) anti-HCV pozitif, 46’sında (% 0,1) VDRL pozitift i. Anti-HIV pozitif olan 54 kişinin (% 0,2) birinde doğrulama testi pozitift i. Araştırmaya alınanların 862’sinde (%2,8) en az bir tane test pozitifl iği vardı. Bir kişide hem HbsAg hemde anti-HCV pozitift i.Sonuç: Donörlerin % 2,8’inde en az bir kanla bulaşan enfeksiyon seropozitifl iği tespit edilmiştir. Seroprevelanserkeklerde yaşla beraber artmaktadır.

🔖

Cite This Article

KURT, A. Ö., ŞAŞMAZ, C. T., ÖNER, S., YAPICI, G., BUĞDAYCI, R. (2022). Hepatitis B, hepatitis C, HIV, and VDRL seroprevalence of blood donors in Mersin. Turkish Journal of Medical Sciences, Cilt: 41 - Sayı: 2, 335–341. https://ajindex.com/articles/611293

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. WHO. Prevention of health care associated HIV infection. Available from: URL: http//www.who.int/bloodsafety/GDBS_ REPORT_2001-2002.pdf 2. WHO. Blood transfusion safety. Available from: URL: http// www.who.int/bloodsafety/en/Blood_Transfusion_Safety.pdf. 3. WHO Europe. Blood safety: a global overview. Copenhagen 10 June 2005 Available from: URL: http://www.euro.who.int/ document/mediacentre/fs0505e.pdf. CDC. Public health service inter-agency guidelines for screening donors of blood, plasma, organs, tissues and semen for evidence. MMWR 1991. WHO/CDS/CSR/LYO/2002.2. Hepatitis B. Available from: URL: http//www.who.int/csr/disease/hepatitis/HepatitisB_ whocdscsrlyo2002_2.pdf. 6. WHO/CDS/CSR/LYO/2003. Hepatitis C. Available from: URL: http//www.who.int/csr/disease/hepatitis/Hepc.pdf. 7. WHO Europe. HIV-AIDS in Europe: Overview 28 Nov. 2005 Kopenhagen. Available from: URL: http//www.euro.who.int/ document/mediacentre/fs1405e.pdf. 8. WHO. AIDE Memoire for National Blood Programs. Blood safety 2002 Available from: URL: http//www.who.int/ bloodsafety/transfusion_services/en/Blood_Safety_Eng.pdf. Kan Ürünlerinin Ruhsatlandırılmasına Dair Yönetmelik. RESMİ GAZETE 20 Mayıs 2002 Sayı: 24760 (in Turkish) Wang B, Schreiber GB, Glynn SA, Nass CC, Smith JW, Higgins MJ et al. Prevalence of transfusion-transmissible viral infections in fi rst-time US blood donors by donation site. Transfusion 2003; 43: 705-12.
  2. Butsashvili M, Tsertsvadze T, McNutt LA, Kamkamidze G, Gvetadze R, Badridze N. Prevalence of hepatitis B, hepatitis C, syphilis and HIV in Georgian blood donors. Eur J Epidemiol 2001; 17: 693-5. Al-Rashed M. Th e prevalence of hepatitis B in blood donors in the middle region of Jordan. Gulhane Tıp Dergisi 2003; 45: 153-5.
  3. Ameen R, Sanad N, Al-Shemmari S, Siddique I, Chowdhury RI, Al-Hamdan S et al. Prevalence of viral markers among fi st- time Arab blood donors in Kuwait. Transfusion 2005; 45: 1973- 80. Bhatti FA, Ullah Z, Salamat N, Ayub M, Ghani E. Anti hepatitis B core antigen testing, viral markers and occult hepatitis B virus infection in Pakistani blood donors: implications for transfusion practice. Transfusion 2007; 47: 74-9.
  4. Gogos CA, Fouka KP, Nikiforidis G, Avgeridis K, Sakellaropoulos G, Bassaris H et all. Prevalence of hepatitis B and C virus infection in the general population and selected groups in South-Western Greece. Eur J Epidemiol 2003; 18: 551-7.
  5. Emekdas G, Cavuşlu Ş, Öncül O, Artuk Ç, Aksoy A. Trends in hepatitis B and C virus among blood donors o